EYELID CANCER: EPIDEMIOLOGY AND PROGNOSIS
https://doi.org/10.17650/2222-1468-2016-6-4-62-65
Abstract
Data on 3597 newly diagnosed patients with malignant tumors of the eye was entered in the Moscow cancer registry during 2006–2015. The frequency of eyelid cancer was 75.62 %, its incidence was 3.4 per 100 000. People usually develop the disease at the age of 46–85 with the peak at 70–80 years. Incidence in females was 66.65 % higher than in males. The rate of basal cell carcinoma was 91.14 %. In 65.7 % of the cases tumor was diagnosed on Т1–2 stages; out of them only 34 % of the patients were diagnosed at T1 stage, when the disease can be completely cured.
About the Authors
A. F. Brovkina
Russian Medical Academy of Сontinuing Рrofessional Education
Russian Federation
Russian Federation
Build. 1, 2/1 Barrikadnaya St., Moscow 125993
M. Yu. Lerner
S.P. Botkin City Clinical Hospital, Branch No 1, Eye Care Service
Russian Federation
Russian Federation
5 2nd Botkinskiy Proezd, Moscow 125284
References
1. Diepgen T.L., Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146 Suppl 6: 1–6.
2. Панова И.Е., Важенин А.В., Усова Р.А. и др. Эпидемиология, клинико-морфологическая характеристика, дифференциальная диагностика базально-клеточного рака кожи век. Челябинск, 2003. 14 c. [Panova E.I., Vazhenin A.V., Usova R.A. et al. Epidemiology, clinical-morphological characteristics, differential diagnosis basal cell carcinoma of the eyelid skin. Chelyabinsk, 2010. 14 p. (In Russ.)].
3. Cook B.E. Jr, Bartley G.B. Treatment options and future prospects for the management of eyelid malignancies: An evidence-based update. Ophthalmology 2001;108(11):2088–98.
4. Murchison A.P., Walrath J.D., Washington C.V. Non-surgical treatments of primary, nonmelanoma eyelid malignancies: a review. Clin Exp Ophthalmol 2011;39(1):65–83. DOI: 10.1111/j.1442-9071.2010.02422.x.
5. Actis A.G., Actis G., De Sanctis U. et al. Eyelid benign and malignant tumors: issues in classification, excision and reconstruction. Minerva Chir 2013;68(6 Suppl 1):11–25.
6. Bagheri A., Тavakoli M., Kanaani A. et al. Eyelid Masses: A 10-year Survey from a Tertiary Eye Hospital in Tehran. Middle East Afr J Ophthalmol 2013;20(3):187–92. DOI:10.4103/0974-9233.114788.
7. Международная классификация онкологических заболеваний-2000. Доступно по: http://who-fic.ru/icd/adaptations/oncology/. [International classification of diseases for оncology-2000. Available at: http://who-fic.ru/icd/adaptations/oncology/. (In Russ.)].
8. Allali J., D’Hermies F., Renard G. Basal cell carcinomas of the eyelids. Ophthalmologica 2005;219(2):57–71.
9. Faustina M., Diba R., Ahmadi M.A., Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology 2004;111(10):1930–32.
10. Lin H.Y., Cheng C.Y., Hsu W.M. et al. Incidence of eyelid cancers in Taiwan: a 21-year review. Ophthalmology 2006;113(11):2101–7.
11. Weinstock M.A., Still J.M. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutan Med Surg 2011;30(4 Suppl):S10–S3. DOI: 10.1016/j.sder.2011.11.004.
12. Asproudis I., Sotiropoulos G., Gartzios C. et al. Eyelid Tumors at the University Eye Clinic of Ioannina, Greece: A 30-year Retrospective Study. Middle East Afr J Ophthalmol 2015;22(2):230–2. DOI: 10.4103/0974-9233.151881.PMCID:PMC4411622.
13. Domingo R.E., Manganip L.E., Castro R.M. Tumors of the eye and ocular adnexa at the Philippine Eye Research Institute: a 10-year review. Clin Ophthalmol 2015;9:1239–47. DOI: 0.2147/OPTH.S87308.
14. Huang Y.Y., Liang W.Y., Tsai C.C. et al. Comparison of the Clinical Characteristics and Outcome of Benign and Malignant Eyelid Tumors: An Analysis of 4521 Eyelid Tumors in a Tertiary Medical Center. Biomed Res Int 2015;2015:453091. DOI: 10.1155/2015/453091.
15. Samarasinghe V., Madan V. Nonmelanoma skin cancer. J Cutan Aesthet Surg 2012;5(3): 3–10. DOI: 10.4103/0974-2077.94323.
16. Sekulic A., Migden M.R., Basset-Seguin N. et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. J Clin Oncol 2013;31(Suppl):abstr 9037.
17. Suzuki H.S., Serafini S.Z., Sato M.S. Utility of dermoscopy for demarcation of surgical margins in Mohs micrographic surgery. An Bras Dermatol 2014;89(1):38–43. DOI: 10.1590/abd1806-4841.20142400.PMCID:PMC3938352.
18. Takamura H., Yamashita H. Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: Statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol 2005;49(5): 349–54.
19. Rene C. Oculoplastic aspects of ocular oncology. Eye (Lond) 2013;27(2):199–207. DOI: 10.1038/eye.2012.243.
20. Kale S.M., Patil S.B., Khare N. et al. Clinicopathological analysis of eyelid malignancies – A review of 85 cases. Indian J Plast Surg 2012;45(1):22–8. DOI: 10.4103/0970-0358.96572.PMCID:PMC3385393.
Review
For citations:
Brovkina A.F., Lerner M.Yu. EYELID CANCER: EPIDEMIOLOGY AND PROGNOSIS. Head and Neck Tumors (HNT). 2016;6(4):62-65. (In Russ.) https://doi.org/10.17650/2222-1468-2016-6-4-62-65
Views:
4742
Email this article 